XAGE-1 mRNA expression in prostate cancer and antibody response in patients

Fumihito Koizumi, Yuji Noguchi, Takashi Saika, Kazuhiko Nakagawa, Shuichiro Sato, Ali Mohamed Ali Eldib, Yasutomo Nasu, Hiromi Kumon, Eiichi Nakayama

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


To evaluate the feasibility of cancer vaccine targeting XAGE-1, we investigated the expression of 4 XAGE-1 transcript variants and the humoral immune response to XAGE-1 in prostate cancer patients. XAGE-1a, b, c, d mRNA expression was analyzed in 54 prostate cancer specimens and 8 specimens of benign prostate hypertrophy (BPH) by reverse transcription-polymerase chain reaction (RT-PCR). The humoral response to XAGE-1 was investigated in sera obtained from 278 patients with prostate cancer and 40 healthy volunteers by enzyme-linked immunosorbent assay (ELISA) using recombinant protein. XAGE-1b mRNA expression was observed in 14 of 54 (26%) prostate cancer specimens, while XAGE-1a, c, and d mRNA expressions were observed in 1,1, and 3, respectively. None of the 4 XAGE-1 transcript variants was observed in the 8 BPH specimens. Antibody against XAGE-1 was detected in sera from 2 of 129 stage D2 patients, whereas none of sera from 149 patients with localized prostate cancer or lymph node metastasis had detectable XAGE-1 antibody. No reactivity to XAGE-1 was found in sera from the 40 healthy individuals.

Original languageEnglish
Pages (from-to)471-476
Number of pages6
Issue number5
Publication statusPublished - 2005


  • Cancer/testis antigen
  • Prostate cancer
  • XAGE-1

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Virology


Dive into the research topics of 'XAGE-1 mRNA expression in prostate cancer and antibody response in patients'. Together they form a unique fingerprint.

Cite this